REAL World Evidence Of The Effectiveness And Clinical Practice Use Of Glecaprevir/Pibrentasvir For 8 Weeks Treatment In Patients With Chronic HepatitiS C GenotYpes 1 to 6 And Liver Cirrhosis In Russian Federation (EASY)
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms EASY
- Sponsors AbbVie
Most Recent Events
- 28 Jun 2021 Status changed from active, no longer recruiting to completed.
- 10 May 2021 Planned End Date changed from 1 Apr 2021 to 2 Jul 2021.
- 10 May 2021 Planned primary completion date changed from 1 Apr 2021 to 2 Jul 2021.